Related Experiment Video
Updated: Feb 22, 2026
Frequency and Distribution of Crossovers in Caenorhabditis elegans Meiosis by SNP Genotyping using Real-time PCR
Published on: July 11, 2025
KRAS Alleles: The Devil Is in the Detail
1Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
Abstract:
KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is, as yet, not directly druggable, efforts to target KRAS mutant cancers focus on identifying vulnerabilities in downstream signaling pathways or in stress response pathways that are permissive for strong oncogenic signaling. One aspect of KRAS biology that is not well appreciated is the potential biological differences between the many distinct KRAS activating mutations. This review draws upon insights from both clinical and experimental studies to explore similarities and differences among KRAS alleles. Historical and emerging evidence supports the notion that the specific biology related to each allele might be exploitable for allele-specific therapy.
Insights
KRAS mutations drive cancer, but targeting them is hard. This review explores differences between KRAS mutations, suggesting allele-specific therapies could be effective for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS is the most frequently mutated oncogene in cancer.
- KRAS mutations are linked to poor prognosis and treatment resistance.
- The KRAS oncoprotein is currently not directly druggable.
Purpose of the Study:
- To explore similarities and differences among various KRAS alleles.
- To investigate the potential for allele-specific therapies in KRAS-mutant cancers.
Main Methods:
- Review of clinical and experimental studies.
- Analysis of KRAS biology and downstream signaling pathways.
- Exploration of stress response pathways in KRAS-driven cancers.
Main Results:
- Distinct KRAS alleles exhibit unique biological characteristics.
- Understanding these differences is crucial for effective cancer targeting.
- Emerging evidence supports the feasibility of allele-specific therapeutic strategies.
Conclusions:
- The specific biology of each KRAS allele presents opportunities for targeted therapies.
- Developing allele-specific treatments could overcome resistance and improve outcomes in KRAS-mutant cancers.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
05:48Removal of an Internal Translational Start Site from mRNA While Retaining Expression of the Full-Length Protein
Published on: March 16, 2022
Related Concept Videos
02:38The Ras Gene
Ras is a...
01:09Epistasis Analysis
02:41Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:35Pedigree Analysis
01:49Multiple Allele Traits
01:39Epistasis